MARX Biotech Co., Ltd. (7731) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of MARX Biotech Co., Ltd. stock TWD 1.39, price TWD 4.03, that is 65.5% below the price, quality 34 out of 100. Rating: strongly overvalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
33‑month range 3.94 TWD – 14.05 TWD · fair‑value band 0.5800 TWD – 2.26 TWD · the 4.03 TWD price screens above the 1.39 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow MARX Biotech Co. in your weekly email
Every Wednesday you see whether MARX Biotech Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
MARX Biotech Co., Ltd. engages in the online retail of men's health food and cosmeceutical products. The company was founded in 2015 and is based in New Taipei City, Taiwan.
Stock analysis
MARX Biotech Co., Ltd. (7731) currently trades at 4.03 TWD, while our model-based Fair Value estimate is 1.39 TWD, 66% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 3.82 TWD per share, and 0 of the 12 models we run sit above the 4.03 TWD price.
Bear case: the Asset-Based group reads lowest at 0.1400 TWD, and 12 of the 12 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.5800 TWD (bear) to 2.26 TWD (bull), the price of 4.03 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
MARX Biotech Co., Ltd. reported revenue of 636M TWD in FY2025 versus 97.6M TWD in FY2021, a compound +59.8%/yr. Reported net income was 42.9M TWD in FY2025, compounding +32.9%/yr from FY2021.
Key figures
Market cap 2.1B TWD (≈ $64.1M) Micro · P/E ratio 57.6 · P/S ratio 3.60 · EPS (TTM) 0.0700 TWD · Dividend yield 1.4% · Net margin 5.5% · Return on equity 12.5% · Return on assets (EBIT) −2.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).
What moves the price
The share trades about 55% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at −66%, 7731 screens richer than that median.
Fair Value models
Bear0.5800 TWDFair Value 1.39 TWDBull2.26 TWD
Price 4.03 TWD · Downside -65.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.0103 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+2.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+79.1%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−2.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.8%
Dividend (yield on the price)1.4%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → −22%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks
Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score34 · Bottom 25%
Fair Value upside−65.5% · Bottom 25%
Profitability
Return on equity (12 months)12.5% · Above median
Return on assets5.2% · Above median
Net margin (12 months)5.5% · Top 25%
Operating margin (12 months)−17.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−16.5% · Bottom 25%
Dividend yield (12 months)1.4% · Below median
Balance sheet
Debt / equity0.46× · Highest 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/E (12 months)57.6× · Priciest 25%
P/B5.85× · Priciest 25%
P/S (12 months)3.60× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 68
FUTURE (revenue growth)0· sector 21
PAST (return on equity)50· sector 32
HEALTH (low debt)77· sector 96
DIVIDEND (yield)29· sector 58
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is MARX Biotech Co., Ltd. (7731) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 1.39 TWD versus a price of 4.03 TWD, about 66% lower (overvalued).
What is the fair value of 7731?
Our model-based fair value for MARX Biotech Co., Ltd. is 1.39 TWD (as of Nov 4, 2026), built from audited fundamentals. The current price: 4.03 TWD.
What is the quality score of 7731?
MARX Biotech Co., Ltd. has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MARX Biotech Co., Ltd. (7731)?
Our model-based price target is the fair value of 1.39 TWD (as of Nov 4, 2026) from 12 valuation models. Cautious scenario 0.5800 TWD, optimistic scenario 2.26 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the MARX Biotech Co., Ltd. stock forecast for 2026?
Our models put fair value at 1.39 TWD, about 66% lower versus a price of 4.03 TWD (overvalued). Cautious scenario 0.5800 TWD, optimistic scenario 2.26 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of MARX Biotech Co., Ltd. (7731)?
MARX Biotech Co., Ltd. reported trailing-twelve-month revenue of about 585M TWD (latest available figure, as of Nov 4, 2026).
Does MARX Biotech Co., Ltd. pay a dividend?
MARX Biotech Co., Ltd. currently shows a dividend yield of 1.44% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of MARX Biotech Co., Ltd. (7731) and when is the ex-dividend date?
MARX Biotech Co., Ltd. pays a dividend of 0.058 TWD per share a year, a dividend yield of 1.4%. The last ex-dividend date was Aug 28, 2026. The payout ratio is 82.9% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of MARX Biotech Co., Ltd. (7731)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MARX Biotech Co., Ltd. it is 1.39 TWD per share (as of Nov 4, 2026), against a price of 4.03 TWD. It is the blended result of 12 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is MARX Biotech Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 7731 trades above its calculated fair value: price 4.03 TWD, fair value 1.39 TWD, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7731?
No. The price is what the market pays today (4.03 TWD); the fair value is what the company's own numbers justify (1.39 TWD). For MARX Biotech Co., Ltd. the two are 2.64 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is MARX Biotech Co., Ltd. worth?
The market values MARX Biotech Co., Ltd. at about 2.1B TWD (market capitalisation, as of Nov 4, 2026). Per share that is 4.03 TWD; our models calculate a fair value of 1.39 TWD per share.
What do the bullish and bearish scenarios say about 7731?
Our models span a range for MARX Biotech Co., Ltd.: cautious scenario 0.5800 TWD, base 1.39 TWD, optimistic 2.26 TWD per share (as of Nov 4, 2026, price 4.03 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 7731?
MARX Biotech Co., Ltd. trades at a price-to-earnings ratio of 57.6 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.39 TWD is built from several models across several years. Other multiples: P/B 5.9, P/S 3.6.
How solid is the balance sheet of MARX Biotech Co., Ltd. (7731)?
Balance-sheet figures for MARX Biotech Co., Ltd. (as of Nov 4, 2026): return on equity 12.5%, debt of 0.46 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is 7731 from its 52-week high?
MARX Biotech Co., Ltd. trades at 4.03 TWD, about 55% below its 52-week high of 9.01 TWD and at the low of 4.03 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1.39 TWD is for.
Which stocks are comparable to MARX Biotech Co., Ltd.?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MARX Biotech Co., Ltd. stock attractive at the current price?
The data as of Nov 4, 2026: price 4.03 TWD, calculated fair value 1.39 TWD (−66%), Quality Score 34/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7731 calculated?
We run MARX Biotech Co., Ltd. through 12 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 1.39 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. MARX Biotech Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MARX Biotech Co., Ltd. (7731)?
The closing price on Nov 6, 2026 was 4.03 TWD. Our model-based fair value is 1.39 TWD, about 66% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MARX Biotech Co., Ltd. right now?
The price sits above even our optimistic bull case (2.26 TWD). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (0.5800 TWD to 2.26 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of MARX Biotech Co., Ltd.
How large is the market capitalisation of MARX Biotech Co., Ltd. (7731)?
The market capitalisation of MARX Biotech Co., Ltd. is 2.1B TWD (≈ $64.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MARX Biotech Co., Ltd. (7731)?
The price-to-sales ratio of MARX Biotech Co., Ltd. is 3.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MARX Biotech Co., Ltd. (7731)?
Earnings per share at MARX Biotech Co., Ltd. are 0.0700 TWD (price ÷ EPS = P/E 57.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of MARX Biotech Co., Ltd. (7731)?
The dividend yield of MARX Biotech Co., Ltd. is 1.4% (payout 82.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of MARX Biotech Co., Ltd. (7731)?
The net margin of MARX Biotech Co., Ltd. is 5.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MARX Biotech Co., Ltd. (7731)?
The return on equity (ROE) of MARX Biotech Co., Ltd. is 12.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MARX Biotech Co., Ltd. (7731)?
On an EBIT basis the return on assets of MARX Biotech Co., Ltd. is −2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MARX Biotech Co., Ltd. (7731)?
The operating margin of MARX Biotech Co., Ltd. is −17.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MARX Biotech Co., Ltd. (7731)?
Revenue at MARX Biotech Co., Ltd. is growing −16.5% versus a year earlier (3y avg +79.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does MARX Biotech Co., Ltd. (7731) generate?
The free cash flow of MARX Biotech Co., Ltd. is −163M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does MARX Biotech Co., Ltd. (7731) carry?
The net debt of MARX Biotech Co., Ltd. is 275M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch MARX Biotech Co., Ltd. in the live analysis
One click puts MARX Biotech Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026